WEKO3
アイテム
Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.
https://repo.qst.go.jp/records/46651
https://repo.qst.go.jp/records/466511bb58961-0f8c-4a6f-85ef-9b09a5c21429
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2013-12-02 | |||||
| タイトル | ||||||
| タイトル | Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kameoka, Yoshihio
× Kameoka, Yoshihio× Takahashi, Naoto× Ishizawa, Keniti× Kato, Yuichi× Ito, Jugo× Sasaki, Osamu× Murai, Katzunori× Noji, Hideyoshi× Hirokawa, Makoto× Tajima, Katsushi× Shichishima, Tsutomu× Ishida, Yoji× Harigae, Hideo× Sawada, Kenichi× 田嶋 克史 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial. Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored. Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen. | |||||
| 書誌情報 |
International Journal of Hematology 巻 96, 号 5, p. 624-30, 発行日 2012-11 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0925-5710 | |||||
